Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Protocol ID
APG-115-US-002
Disease (Sub Disease)
Melanoma
Solid tumours
Solid tumours
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Relapse/Refractory
Sponsor
Ascentage Pharma Group Inc.
Collaborators
Merck Sharp & Dohme Corp.
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
12 Years and older
International registry ID's
NCT03611868
| Study Title | A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors |
|---|---|
| Protocol ID | APG-115-US-002 |
| Disease (Sub Disease) | Melanoma Solid tumours |
| Diagnosis Stage | New Diagnosis Relapse/Refractory |
| Sponsor | Ascentage Pharma Group Inc. |
| Collaborators | Merck Sharp & Dohme Corp. |
| Links | https://clinicaltrials.gov/ct2/show/NCT03611868 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 29/08/2018 |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 12 Years and older |
| International registry ID's | NCT03611868 |